Search Results - Steven D. Gore

Refine Results
  1. 1
    Arsenic trioxide — An old drug rediscovered

    Arsenic trioxide — An old drug rediscovered by Ashkan Emadi, Steven D. Gore

    Published 2010
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Epigenetic Therapies in MDS and AML

    Epigenetic Therapies in MDS and AML by Elizabeth A. Griffiths, Steven D. Gore

    Published 2012
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

    DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes by Elizabeth A. Griffiths, Steven D. Gore

    Published 2008
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Current therapy of myelodysplastic syndromes

    Current therapy of myelodysplastic syndromes by Amer M. Zeidan, Yuliya Linhares, Steven D. Gore

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Iron chelation therapy in myelodysplastic syndromes: where do we stand?

    Iron chelation therapy in myelodysplastic syndromes: where do we stand? by Mhairi Mitchell, Steven D. Gore, Amer M. Zeidan

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions

    Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions by Tae Kon Kim, Steven D. Gore, Amer M. Zeidan

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

    Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings by Brian Ball, Amer M. Zeidan, Steven D. Gore, Thomas Prébet

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Current developments in T-cell receptor therapy for Acute Myeloid Leukaemia

    Current developments in T-cell receptor therapy for Acute Myeloid Leukaemia by Steven D. Gore, Emily Blyth, Marie Bleakley, Koon Lee, Kenneth Micklethwaite, Kavitha Gowrishankar

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes

    Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes by Tamer E. Fandy, Anchalee Jiemjit, Manjusha Thakar, Paulette Rhoden, Lauren Suarez, Steven D. Gore

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Equitable Access to Clinical Trials: How Do We Achieve It?

    Equitable Access to Clinical Trials: How Do We Achieve It? by Ana Acuña-Villaorduña, Joaquina Baranda, Jessica Boehmer, Lola A. Fashoyin‐Aje, Steven D. Gore

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Epigenetics in Cancer: A Hematological Perspective

    Epigenetics in Cancer: A Hematological Perspective by Maximilian Stahl, Nathan Kohrman, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan, Thomas Prébet

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials

    A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials by Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji, Steven D. Gore

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage

    p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage by Anchalee Jiemjit, Tamer E. Fandy, Hetty E. Carraway, Kayleen Bailey, Stephen B. Baylin, James G. Herman, Steven D. Gore

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse

    Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse by Scott H. Kaufmann, Judith E. Karp, Phyllis A. Svingen, Stan Krajewski, Philip J. Burke, Steven D. Gore, John C. Reed

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes

    Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes by Amer M. Zeidan, Franklin Hendrick, Erika Friedmann, Maria R. Baer, Steven D. Gore, Medha Sasané, Carole Paley, Amy J. Davidoff

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies

    Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies by Michelle A. Rudek, Ming Zhao, Ping He, Carol Hartke, Jill Gilbert, Steven D. Gore, Michael A. Carducci, Sharyn D. Baker

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse

    Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse by Scott H. Kaufmann, Judith E. Karp, Phyllis A. Svingen, Stan Krajewski, Philip J. Burke, Steven D. Gore, John C. Reed

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation

    5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation by Javier Bolaños‐Meade, Benjamin D. Smith, Steven D. Gore, Michael A. McDevitt, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

    Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure by Thomas Prébet, Steven D. Gore, Sylvain Thépot, Benjamin Esterni, Bruno Quesnel, Odile Beyne Rauzy, François Dreyfus, Claude Gardin, Pierre Fenaux, Norbert Vey

    Published 2012
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  20. 20
    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

    Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies by Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: